[Ramucirumab for advanced gastric or gastroesophageal junction cancer]
Oubiña M, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001442
Spanish
Original Title:
Ramucirumab en cáncer gástrico o de la unión gastro-esofágica avanzado
Authors' recommendations:
CONCLUSIONS
Moderate-quality evidence shows that in patients with advanced gastric or gastroesophageal junction cancer, the use of ramucirumab as second line therapy alone or in combination with paclitaxel is associated to an increase of approximately two months in overall survival. In terms of safety, the most significant adverse event observed is arterial hypertension.
The clinical practice guidelines from the main Oncology Societies recommend this treatment both as monotherapy and in combination with paclitaxel in patients who have presented disease progression after first line therapy with fluoropyrimidines or platinum.
Some health sponsors surveyed cover this treatment. No cost-effectiveness studies have been found in Argentina.
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Peritoneal Neoplasms
- Stomach Neoplasms
- Esophagogastric Junction
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.